01:06 PM EST, 12/23/2024 (MT Newswires) -- Astrazeneca ( AZN ) said Monday the European Commission approved Tagrisso for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer whose tumours have epidermal growth factor receptor exon 19 deletions or exon 21 substitution mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy.

The approval follows the recommendation of the EU Committee for Medicinal Products for Human Use and is based on late-stage trial results that showed Tagrisso extended median progression-free survival to more than three years.

Price: 66.07, Change: +0.72, Percent Change: +1.10